DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20200179

Efficacy of orlistat in the treatment of patients with non-alcoholic fatty liver

Manouchehr Iranparvar Alamdari, Shahram Habibzadeh, Ahad Azami, Babak Shirinzadeh, Roghayeh Aslanian, Kiana Yazdanbod

Abstract


Background: Nonalcoholic fatty liver disease (NAFLD) is a reversible condition of fat accumulation that is associated with liver inflammation and can disrupt the normal activity of the liver. People with a diagnosis of NAFLD have a higher risk of all- cause mortality than the general population. The purpose of the present study was to determine, the efficacy of orlistat in the treatment of patients with NAFLD.

Methods: This semi-experimental study was performed on 45 fatty liver patients of the gastroenterology clinic of Imam Khomeini Hospital in Ardabil city in April 2016 to April 2017. Data was collected by a checklist which included demographic and clinical data such as age, sex, body mass index (BMI), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), cholesterol and result of ultrasound before and after orlistat consumption.

Results: The mean decrease in the variables examined was as follows: weight 8.3 kg, BMI 3.5 kg/m2, ALT 31.6 U/l, AST 18.1 U/l, cholesterol 15.5 mg/dl and TG 33.1 mg/dl. All of the upper indexes were decreased significantly following received drug.

Conclusions: Orlistat therapy was associated with significant decreases in ALT, AST, TG and cholesterol level. Orlistat is effective in weight loss, body mass index reduction and can be used to treat non-alcoholic fatty liver disease.


Keywords


Ardabil, Fatty liver, Orlistat

Full Text:

PDF

References


Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95.

Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Japanese J Med. 1988;27:142-9.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-23.

Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgraduate Med J. 2006;82:315-22.

Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647-54.

Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2006;46:39-44.

Guerciolini R. Mode of action of orlistat. International journal of obesity and related metabolic disorders. J Int Association Study Obesity. 1997;21:12-23.

Björnsson E, Angulo P. Non-alcoholic fatty liver disease. Scandinavian J Gastroenterol. 2007;42:1023-30.

Lonardo A, Loria P. NAFLD and cardiovascular risk: direct evidence for the tale of two ages. The American J Gastroenterol. 2009;104:1851.

Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Seminars Liver Dis. 2001;21:17-26.

Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Digest Dis. 2010;28:155-61.

Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients. Alimentary Pharmacol Therap. 2004;20:623-8.

Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-42.

Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. The American J Cardiol. 1998;81:18-25.

Gabriel FS, Samson CE, Abejuela ZR, Sicat-Gabriel PR, Sumpio JP, Zacarias MB, et al. Postprandial effect of orlistat on the peaking of lipid level after sequential high fat meals. Int J Endocrinol Metabol. 2012;10:458.

Smith SR, Stenlof KS, Greenway FL, McHutchison J, Schwartz SM, Dev VB, et al. Orlistat 60 mg Reduces Visceral Adipose Tissue: A 24‐Week Randomized, Placebo‐Controlled, Multicenter Trial. Obesity. 2011;19:1796-803.

Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial. Diabetes Obes Metabol. 2002;4:415-23.

Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes. 2000;24:306.

Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2018;9:90-6.